У нас вы можете посмотреть бесплатно Osteobites: Chromosomal Instability and Osteosarcoma Patient Outcomes или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Osteosarcoma Webinar Series: OsteoBites welcomes Yanding Zhao, PhD to discuss how Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes Osteosarcoma (OS) is the most common primary bone cancer in children and young adults. Despite its aggressive course—marked by a 30% five-year mortality rate for metastatic cases—treatment has remained unchanged for decades. OS is notable for extreme chromosomal instability (CIN) and molecular heterogeneity, which have hindered therapeutic progress. To address this, researchers performed longitudinal and multi-modal profiling of 91 tumors from 71 pediatric patients, integrating whole-genome and transcriptome sequencing with ATAC-seq and Hi-C in matched cell lines. Their analyses revealed that key driver mutations, including TP53, are fixed early and persist through progression. Over 80% of tumors exhibited complex structural alterations—such as chromothripsis, kataegis, loss of heterozygosity, and ecDNA amplification—with MYC enhancer hijacking linked to chemoresistance. They identified a high-risk evolutionary trajectory marked by homologous recombination deficiency (HRD)-like signatures in the absence of BRCA mutations. These tumors showed focal duplications at fragile sites, early whole-genome doubling, high TP53 mutation burden, and sensitivity to PARP inhibition—highlighting a potential therapeutic vulnerability. Together, their findings define a replication stress–driven model of OS evolution, shaped by early chromosomal remodeling and ecDNA-mediated oncogene activation, with implications for biomarker development and precision treatment strategies. Dr. Yanding Zhao is a postdoctoral researcher at Stanford University in the lab of Dr. Christina Curtis. He earned his PhD in Genetics from Dartmouth College, where he began developing computational tools to understand how genome instability disrupts gene regulation in cancer. At Stanford, his research focuses on pediatric osteosarcoma. By combining genome sequencing, 3D chromatin mapping, and spatial transcriptomics, he studies how tumors evolve, resist treatment, and evade the immune system. Dr. Zhao works closely with clinicians and scientists to help turn these discoveries into potential new therapies. He is honored to be part of the MIB Agents community and looks forward to sharing his work in a way that resonates with patients, families, and advocates. --- You're not alone. We're here for you. 💙 --- What are OsteoBites? OsteoBites are weekly webinars and podcasts presented by MIB Agents, an organization dedicated to Making It Better for children with osteosarcoma. We offer education, support, and advocacy for families facing this challenging disease. Learn more about our mission and programs at https://www.mibagents.org ---- Want to support our mission? Donate here: https://give-usa.keela.co/embed/YAipu... --- Factor 2025 Registration - https://www.mibagents.org/research/fa... ---- Bing Osteosarcoma Auction - https://tockify.com/mibagents/detail/... Instagram - / mib.agents X - https://x.com/AgentsMIB Facebook - / mibagents Stay updated with the latest news and events: https://www.mibagents.org/how-to-help...